Timeliness and actionable intelligence over I-Banks research which remains only geared to institutional investors and legacy processes. News carries with it a promise of transparency, a light that can be shined into previously dark corners.
But they don’t define any relevance to the actual value of a release - mostly due to SEC forward looking parameters. However, this news portal has been expanded to … supplement, measure and price the event and relevance to a company’s ... valuation.
February 8, 2023
Cellectis SA (CLLS) closes 9.9 M ADS offering at $2.50
January 25, 2023
Precigen (PGEN) $75 M offering priced at $1.75
January 18, 2023
bluebird bio (BLUE) prices offering of 20 M shares at $6.00
January 9, 2023
RegMed Investors (RMi) Research Note: News related to JPM23
December 31, 2022
RegMed Investors (RMi): Happy New Year – 2023
December 24, 2022
Merry Christmas and Happy Holiday to All
September 28, 2022
RegMed Investors’ (RMi): What’s up Applied Genetic Technologies (AGTC)?
September 21, 2022
bluebird bio (BLUE) announced the FDA has granted Accelerated Approval of SKYSONA® (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystro
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors